Morphine News and Research

Latest Morphine News and Research

Study: OEND effectively addresses epidemic of fatal opioid overdose

In a study of communities in Massachusetts with high numbers of opioid overdose deaths, the implementation of overdose education and naloxone distribution (OEND) was associated with a significant reduction in opioid overdose death rates.

2 Feb 2013

Itch-specific nerve cells: an interview with Associate Professor Xinzhong Dong

Itch was actually defined by a German physician more than 350 years ago. His name was Samuel Hafenreffer. He defined itch as an unpleasant sensation that makes people want to scratch. You probably think this is a very simple definition but itch is really a very complex sensory modality.

21 Jan 2013

QrxPharma to resubmit MOXDUO NDA with FDA

QRxPharma Limited announced today that the steps necessary for approval of immediate release MOXDUO have been clarified with the United States Food and Drug Administration (FDA).

17 Jan 2013

Morphine not first choice after neonatal surgery

Neonates and infants undergoing major surgery should be treated with postoperative intermittent intravenous acetaminophen as opposed to continuous morphine, research suggests.

14 Jan 2013

Researchers discover new pathway to reduce paradoxical pain

For individuals with agonizing pain, it is a cruel blow when the gold-standard medication actually causes more pain. Adults and children whose pain gets worse when treated with morphine may be closer to a solution, based on research published in the January 6 on-line edition of Nature Neuroscience.

7 Jan 2013

Itch-specific nerve cells in skin discovered by John Hopkins scientists

Johns Hopkins researchers have uncovered strong evidence that mice have a specific set of nerve cells that signal itch but not pain, a finding that may settle a decades-long debate about these sensations, and, if confirmed in humans, help in developing treatments for chronic itch, including itch caused by life-saving medications.

3 Jan 2013

Electroconvulsive therapy releases opiate-like substances

Researchers used electricity on certain regions in the brain of a patient with chronic, severe facial pain to release an opiate-like substance that's considered one of the body's most powerful painkillers.

3 Jan 2013

Johns Hopkins scientists uncover itch-specific nerve cells in skin

3 Jan 2013

Study suggests genetic component in pain response among children

At least two common gene variants are linked to "clinically meaningful" differences in pain scores in children after major surgery, reports a study in the January issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

25 Dec 2012

People with chronic shortness of breath may soon have new way to help alleviate their discomfort

People experiencing chronic shortness of breath may soon have a new way to help alleviate their discomfort, according to a Penn State College of Medicine pulmonology researcher.

20 Dec 2012

AcelRx announces top-line data from Sufentanil NanoTab PCA System Phase 3 trial

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that top-line data from its previously announced open-label, active-comparator study of its lead product candidate, the Sufentanil NanoTab PCA System, will be featured in poster presentations to be held at the 66th annual New York State Society of Anesthesiologists PostGraduate Assembly meeting in New York City to be held December 14-18, 2012.

15 Dec 2012

Opioids already in the body can enhance malignant tendencies of human cancer cells

A study led by University of Chicago researcher Patrick A. Singleton, Ph.D. and published in the journal Anesthesiology has shown that, even without the addition of further opioids such as morphine, opioids already in the body can enhance the malignant tendencies of human cancer cells.

13 Dec 2012

Pain can be treated by targeting immune and nerve cells outside brain or spinal cord

The treatment of inflammatory pain can be improved by endogenous opioid peptides acting directly in injured tissue. Scientists at the Charité - Universitätsmedizin Berlin and the Université Paris Descartes showed that pain can be successfully treated by targeting immune and nerve cells outside the brain or spinal cord.

3 Dec 2012

Viewpoints: Sen. Corker's plan to avoid the 'fiscal cliff'; Romney's brave attempt to deal with health entitlements; Fixing the drug shortage

I have shared with House and Senate leaders as well as the White House a 242-page bill that, along with other agreed-upon cuts that are to be enacted, would produce $4.5 trillion in fiscal reforms and replace sequestration.

27 Nov 2012

AcelRx commences dosing in ARX-04 sufentanil NanoTab Phase 2 study for acute and breakthrough pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it has dosed the first subjects in a Phase 2, placebo-controlled, dose-finding study of its ARX-04 sufentanil NanoTab product candidate.

5 Nov 2012

Medication at end of life indicates care quality

Medication given to patients at the end of life varies according to whether they are being cared for in a hospice or hospital, and has the potential to indicate the quality of their care, suggest researchers.

24 Oct 2012

FTC votes to approve Watson's acquisition of Actavis

Watson Pharmaceuticals, Inc. today announced that the Federal Trade Commission (FTC) has voted to approve Watson's acquisition of the Actavis group of companies.

16 Oct 2012

QRxPharma, Paladin execute licensing agreement for MOXDUO

QRxPharma Limited announced today execution of a licensing agreement with Paladin Labs Inc. for the Canadian commercialisation rights to MOXDUO, a patented, immediate release formulation of morphine and oxycodone.

10 Oct 2012

Morphine inhibits BDNF protein, whereas cocaine enhances BDNF

Chronic morphine exposure has the opposite effect on the brain compared to cocaine in mice, providing new insight into the basis of opiate addiction, according to Mount Sinai School of Medicine researchers. They found that a protein called brain-derived neurotrophic factor (BDNF), which is increased in cocaine addiction, is inhibited in opioid addiction. The research is published in the October 5 issue of Science.

8 Oct 2012